{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T04:05:47Z","timestamp":1751688347738,"version":"3.41.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-025-01678-y","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T07:46:43Z","timestamp":1745826403000},"page":"734-747","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rare Genetic and Uncommon Morphological Entities in Adults with Acute Myeloid Leukemia"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5332-2404","authenticated-orcid":false,"given":"Xavier","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"1678_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"1678_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"1678_CR3","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1182\/bloodadvances.2023010173","volume":"7","author":"E Attardi","year":"2023","unstructured":"Attardi E, Savi A, Borsellino B, Piciocchi A, Cipriani M, Ottone T, et al. Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting. Blood Adv. 2023;7:5122\u201331.","journal-title":"Blood Adv"},{"key":"1678_CR4","doi-asserted-by":"crossref","unstructured":"Thomas XG. Rare acute leukemias. SM Ansell, editor Rare hematological malignancies. Springer. 2008; 149\u2013191.","DOI":"10.1007\/978-0-387-73744-7_7"},{"key":"1678_CR5","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukaemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"1678_CR6","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"1678_CR7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the united Kingdom medical research Council trials. Blood. 2010;116:354\u201365.","journal-title":"Blood"},{"key":"1678_CR8","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JE, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"1678_CR9","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"1678_CR10","doi-asserted-by":"crossref","unstructured":"Rowe JM. Optimal induction and post-remission therapy for AML in first remission. Hematol Am Soc Educ Program. 2009;2009:396\u2013405.","DOI":"10.1182\/asheducation-2009.1.396"},{"key":"1678_CR11","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJM199410063311402","volume":"331","author":"RJ Mayer","year":"1994","unstructured":"Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and leukemia group B. N Engl J Med. 1994;331:896\u2013903.","journal-title":"N Engl J Med"},{"key":"1678_CR12","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1182\/blood.V88.8.2841.bloodjournal8882841","volume":"88","author":"JK Weick","year":"1996","unstructured":"Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with Daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest oncology group study. Blood. 1996;88:2841\u201351.","journal-title":"Blood"},{"key":"1678_CR13","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","volume":"364","author":"B L\u00f6wenberg","year":"2011","unstructured":"L\u00f6wenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364:1027\u201336.","journal-title":"N Engl J Med"},{"key":"1678_CR14","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2009.813","volume":"301","author":"J Koreth","year":"2009","unstructured":"Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301:2349\u201361.","journal-title":"JAMA"},{"key":"1678_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40164-024-00487-6","volume":"13","author":"H Zhang","year":"2024","unstructured":"Zhang H, Zheng X, Guo W, Xia Y, Zhang R, Zhai W, et al. Outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system. Exp Hematol Oncol. 2024;13:16.","journal-title":"Exp Hematol Oncol"},{"key":"1678_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1200\/JCO.2013.51.8571","volume":"32","author":"R Willemze","year":"2014","unstructured":"Willemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ, et al. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol. 2014;32:219\u201328.","journal-title":"J Clin Oncol"},{"key":"1678_CR17","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1182\/bloodadvances.2018026625","volume":"3","author":"R Bassan","year":"2019","unstructured":"Bassan R, Intermesoli T, Masciulli A, Pavoni C, Boschini C, Gianfaldoni C, et al. Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. Blood Adv. 2019;3:1103\u201317.","journal-title":"Blood Adv"},{"key":"1678_CR18","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1182\/blood.V93.8.2478","volume":"93","author":"EH Estey","year":"1999","unstructured":"Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, et al. Randomized phase II study of fludarabine\u2009+\u2009cytosine arabinoside\u2009+\u2009idarubicin +\/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999;93:2478\u201384.","journal-title":"Blood"},{"key":"1678_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2005-08-3294","volume":"108","author":"S Faderl","year":"2006","unstructured":"Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006;108:45\u201351.","journal-title":"Blood"},{"key":"1678_CR20","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1200\/JCO.2011.37.1286","volume":"30","author":"J Holowiecki","year":"2012","unstructured":"Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, et al. Cladribine, but not fludarabine, added to Daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol. 2012;30:2441\u20138.","journal-title":"J Clin Oncol"},{"key":"1678_CR21","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00280-019-03825-2","volume":"83","author":"S Adige","year":"2019","unstructured":"Adige S, Lapidus RG, Carter-Cooper BA, Dyffy A, Patzke C, Law JY, et al. Equipotent doses of Daunorubicin and Idarubicin for AML: a meta-analysis of clinical trials versus in vitro Estimation. Cancer Chemother Pharmacol. 2019;83:1105\u201312.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1678_CR22","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of Gemtuzumab Ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15:986\u201396.","journal-title":"Lancet Oncol"},{"key":"1678_CR23","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","volume":"125","author":"AK Burnett","year":"2015","unstructured":"Burnett AK, Russell NH, Hills RK, Kell J, Vavenagh J, Kjeldsen L, et al. A randomized comparison of Daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML 17 trial in 1206 patients. Blood. 2015;125:3878\u201385.","journal-title":"Blood"},{"key":"1678_CR24","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1182\/blood-2022-157126","volume":"140","author":"C R\u00f6llig","year":"2022","unstructured":"R\u00f6llig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Harbst R, et al. Single versus double induction with 7\u2009+\u20093 containing 60 versus 90\u00a0mg Daunorubicin for newly diagnosed AML: results from the randomized controlled SAL Dauno-double trial. Blood. 2022;140:523\u20135.","journal-title":"Blood"},{"key":"1678_CR25","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Woerzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-lebel, phase III trial of decitabine versus patient choice, with physician advise, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670\u20137.","journal-title":"J Clin Oncol"},{"key":"1678_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Sellestag D, Jang JH, et al. International phase 3 study of Azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >\u200930% blasts. Blood. 2015;126:291\u20139.","journal-title":"Blood"},{"key":"1678_CR27","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137\u201345.","journal-title":"Blood"},{"key":"1678_CR28","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat VA, Thirman MJ, Garcia JS, D\u00f6hner H, et al. Long-term follow-up of VIALE-A: venetoclax and Azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99:615\u201324.","journal-title":"Am J Hematol"},{"key":"1678_CR29","doi-asserted-by":"publisher","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","volume":"7","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020;7:e724\u201336.","journal-title":"Lancet Haematol"},{"key":"1678_CR30","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"1678_CR31","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","volume":"102","author":"M Aiba","year":"2023","unstructured":"Aiba M, Shigematsu A, Suzuki T, Miyagishima T. Shorter duration of venetoclax administration to 14 days has the same efficacy and better safety profile in treatment of acute myeloid leukemia. Ann Hematol. 2023;102:541\u20136.","journal-title":"Ann Hematol"},{"key":"1678_CR32","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1200\/JCO.21.02823","volume":"40","author":"TM Kadia","year":"2022","unstructured":"Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, et al. Phase II study of venetoclax added to cladribine plus low-dose cytarabine alterning with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2022;40:3848\u201357.","journal-title":"J Clin Oncol"},{"key":"1678_CR33","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3390\/jcm13030876","volume":"13","author":"S Papadakis","year":"2024","unstructured":"Papadakis S, Liapis I, Papadhimitriou SI, Spanoudakis E, Kotsianidis I, Liapis K. Approach to acute myeloid leukemia with increased eosinophils and basophils. J Clin Med. 2024;13:876.","journal-title":"J Clin Med"},{"key":"1678_CR34","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/ajh.26700","volume":"97","author":"G Borthakur","year":"2022","unstructured":"Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo CD, et al. Retrospective comparison of survival and responses to fludarabine, cytarabine, GCSF (FLAG) in combination with Gemtuzumab Ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol. 2022;97:1427\u201334.","journal-title":"Am J Hematol"},{"key":"1678_CR35","first-page":"163","volume":"4","author":"H Kantarjian","year":"2023","unstructured":"Kantarjian H, Borthakur G, Daver N, DiNardo CD, Issa G, Jabbour E, et al. Current status and research directions in acute myeloid leukemia. Blood Cancer J. 2023;4:163.","journal-title":"Blood Cancer J"},{"key":"1678_CR36","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/blood.V122.21.357.357","volume":"122","author":"G Marcucci","year":"2013","unstructured":"Marcucci G, Geyer S, Ahao J, Caroll AJ, Bucci D, Vij R, et al. Adding the KIT inhibitor dasatinib (DAS) to standard induction and consolidation therapy for newly diagnosed patients (pts) with core binding factor (CBF) acute myeloid leukemia (AML): initial results of the CALGB 10801 (Alliance) study. Blood. 2013;122:357.","journal-title":"Blood"},{"issue":"suppl1","key":"1678_CR37","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1182\/blood-2024-194384","volume":"144","author":"I Aldoss","year":"2024","unstructured":"Aldoss I, Issa GC, Blachly JS, Thirman MJ, Mannis GN, Arellano ML, et al. Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in all patients with relapsed or refractory (R\/R) KMT2Ar acute leukemia. Blood. 2024;144(suppl1):211.","journal-title":"Blood"},{"key":"1678_CR38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa GC, Aldoss I, Thirman MJ, et al. Menin Inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2025;43:75\u201385.","journal-title":"J Clin Oncol"},{"key":"1678_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41408-021-00603-3","volume":"12","author":"W Fiskus","year":"2022","unstructured":"Fiskus W, Boettcher S, Daver N, Mill CP, Birdwell CE, Davis JA, et al. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer. 2022;12:5.","journal-title":"Blood Cancer"},{"issue":"suppl1","key":"1678_CR40","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1182\/blood-2024-204375","volume":"144","author":"GC Issa","year":"2024","unstructured":"Issa GC, Cuglievan B, Daver N, DiNardo CD, Farhat A, Short NJ, et al. Phase I\/II study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in R\/R AML. Blood. 2024;144(suppl1):216.","journal-title":"Blood"},{"issue":"suppl1","key":"1678_CR41","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1182\/blood-2024-207106","volume":"144","author":"E Searle","year":"2024","unstructured":"Searle E, Recher C, Abdul-Hay M, Abedin S, Aldoss I, Pierola AA, et al. Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed\/refractory acute leukemia patients with KMT2A and NPM1 alterations. Blood. 2024;144(suppl1):212.","journal-title":"Blood"},{"issue":"suppl1","key":"1678_CR42","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/blood-2024-207072","volume":"144","author":"C Recher","year":"2024","unstructured":"Recher C, O\u2019Nions J, Aldoss I, Pierola AA, Allred A, Alonso-Dominguez JM, et al. Phase 1b study of menin-KMT2A inhibitor bleximenib in combination with intensive chemotherapy in newly diagnosed acute myeloid leukemia with KMT2A or NPM1 alterations. Blood. 2024;144(suppl1):215.","journal-title":"Blood"},{"issue":"suppl1","key":"1678_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2020-134942","volume":"136","author":"ES Wang","year":"2020","unstructured":"Wang ES, Altman JK, Pettit K, de Botton S, Walter RP, Fenaux P, et al. Preliminary data on a phase 1\/2A first in human study of the menin-KMT2A (MLL) inhibitor KO-539 in patients with relapsed or refractory acute myeloid leukemia. Blood. 2020;136(suppl1):7\u20138.","journal-title":"Blood"},{"issue":"suppl1","key":"1678_CR44","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1182\/blood-2024-194827","volume":"144","author":"JF Zeidner","year":"2024","unstructured":"Zeidner JF, Yuda J, Watts JM, Levis MJ, Erba HP, Fukushima K, et al. Phase 1 results: first-in-human phase 1\/2 study of the menin-MLL inhibitor Enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia. Blood. 2024;144(suppl1):213.","journal-title":"Blood"},{"issue":"suppl1","key":"1678_CR45","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1182\/blood-2024-198218","volume":"144","author":"AM Zeidan","year":"2024","unstructured":"Zeidan AM, Wang ES, Issa GC, Erba H, Altman JK, Balasubramanian SK, et al. Ziftomenib combined with intensive induction (7\u2009+\u20093) in newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemia: interim phase 1a results from KOMET-007. Blood. 2024;144(suppl1):214.","journal-title":"Blood"},{"key":"1678_CR46","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/s41379-021-00741-w","volume":"34","author":"H Fang","year":"2021","unstructured":"Fang H, Yabe M, Zhang X, Kim Y, Wu X, Wei P, et al. Myelodysplastic syndrome with t(6;9)(p22;q34.1)\/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. Mod Pathol. 2021;34:1143\u201352.","journal-title":"Mod Pathol"},{"key":"1678_CR47","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","volume":"99","author":"C Thiede","year":"2002","unstructured":"Thiede C, Steudel C, Mohr B, Schaich M, Sch\u00e4kel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326\u201335.","journal-title":"Blood"},{"key":"1678_CR48","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/gcc.22936","volume":"60","author":"C Orsmark-Pietras","year":"2021","unstructured":"Orsmark-Pietras C, Landberg N, Lorenz F, Uggla B, H\u00f6glund M, Lehman S, et al. Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study. Genes Chromosomes Cancer. 2021;60:426\u201333.","journal-title":"Genes Chromosomes Cancer"},{"key":"1678_CR49","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41408-024-01069-9","volume":"14","author":"C Gondran","year":"2024","unstructured":"Gondran C, Dumas PY, Berard E, Bidet A, Delabesse E, Tavitian S, et al. Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)\/BCR::ABL1. A DATAML registry study. Blood Cancer J. 2024;14:91.","journal-title":"Blood Cancer J"},{"key":"1678_CR50","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/onco3030011","volume":"3","author":"S Mohanty","year":"2023","unstructured":"Mohanty S. NUP98 rearrangements in AML: molecular mechanisms and clinical implications. Onco. 2023;3:147\u201364.","journal-title":"Onco"},{"key":"1678_CR51","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/genes12060924","volume":"12","author":"J Quessada","year":"2021","unstructured":"Quessada J, Cuccuini W, Saultier P, Loosveld M, Harrison CJ, Lafage-Pochitaloff M. Cytogenetics of pediatric acute myeloid leukemia: a review of the current knowledge. Genes. 2021;12:924.","journal-title":"Genes"},{"key":"1678_CR52","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.3324\/haematol.2022.281653","volume":"20","author":"EJM Bertrums","year":"2023","unstructured":"Bertrums EJM, Smith JL, Harmon L, Ries RE, Wang YCJ, Alonzo TA, et al. Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. Haematologica. 2023;20:2044\u201358.","journal-title":"Haematologica"},{"key":"1678_CR53","doi-asserted-by":"crossref","unstructured":"Niktoreh N, Walter C, Zimmermann M, von Neuhoff C, von Neuhoff N, Rasche M et al. Mutated WT1, FLT3-ITD, and NUP98-NSD1 fusion in various combinations define a poor prognostic group in pediatric acute myeloid leukemia. J Oncol. 2019;2019:1609128.","DOI":"10.1155\/2019\/1609128"},{"key":"1678_CR54","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/gcc.22064","volume":"52","author":"N Shiba","year":"2013","unstructured":"Shiba N, Ichikawa H, Taki T, Park MJ, Jo A, Mitani S, et al. NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia. Genes Chromosomes Cancer. 2013;52:683\u201393.","journal-title":"Genes Chromosomes Cancer"},{"key":"1678_CR55","doi-asserted-by":"crossref","unstructured":"Thol F, K\u00f6lking B, Hollink IH, Damm F, van den Heuvel-Eibrink MM, Zwaan M et al. Analysis of NUP98\/NSD1 translocations in adult AML and MDS patients. Leukemia. 2013;27:750\u20134.","DOI":"10.1038\/leu.2012.249"},{"key":"1678_CR56","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/sj.leu.2404130","volume":"20","author":"SP Romana","year":"2006","unstructured":"Romana SP, Radford-Weiss I, Ben Abdelali R, Schluth C, Petit A, Dastugue N, et al. NUP98 rearrangements in hematopoietic malignancies: a study of the groupe Francophone de cytog\u00e9n\u00e9tique h\u00e9matologique. Leukemia. 2006;20:696\u2013706.","journal-title":"Leukemia"},{"key":"1678_CR57","doi-asserted-by":"publisher","first-page":"10559","DOI":"10.2147\/OTT.S273172","volume":"13","author":"S Tao","year":"2020","unstructured":"Tao S, Song L, Deng Y, Chen Y, Shi Y, Gan Y, et al. Acute myeloid leukemia with NUP98-RARG gene fusion similar to acute promyelocytic leukemia: case report and literature review. Onco Targets Ther. 2020;13:10559\u201366.","journal-title":"Onco Targets Ther"},{"key":"1678_CR58","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1002\/ajh.25807","volume":"95","author":"HH Zhu","year":"2020","unstructured":"Zhu HH, Yang MC, Wang F, Lou YJ, Jin J, Li K, et al. Identification of a novel NUP98-RARA fusion transcript as the 14th variant of acute promyelocytic leukemia. Am J Hematol. 2020;95:e184\u20136.","journal-title":"Am J Hematol"},{"key":"1678_CR59","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al. The Menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615:920\u20134.","journal-title":"Nature"},{"key":"1678_CR60","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cancergen.2019.03.002","volume":"233\u2013234","author":"Z Tang","year":"2019","unstructured":"Tang Z, Tang G, Hu S, Patel KP, Yin CC, Wang W, et al. Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations. Cancer Genet. 2019;233\u2013234:21\u201331.","journal-title":"Cancer Genet"},{"key":"1678_CR61","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/gcc.22341","volume":"55","author":"C Baldazzi","year":"2016","unstructured":"Baldazzi C, Luatti S, Zuffa E, Papayannidis C, Ottaviani E, Marzocchi G, et al. Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities. Genes Chromosomes Cancer. 2016;55:375\u201388.","journal-title":"Genes Chromosomes Cancer"},{"key":"1678_CR62","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/blood.2019003701","volume":"136","author":"S Ottema","year":"2020","unstructured":"Ottema S, Mulet-Lazaro R, Beverloo HB, Erpelinck C, van Herk S, van der Helm R, et al. Atypical 3q26\/MECOM rearrangements genocopy inv(3)\/t(3;3) in acute myeloid leukemia. Blood. 2020;136:224\u201334.","journal-title":"Blood"},{"key":"1678_CR63","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1200\/JCO.2010.29.2771","volume":"28","author":"S Lugthart","year":"2010","unstructured":"Lugthart S, Gr\u00f6schel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol. 2010;28:3890\u20138.","journal-title":"J Clin Oncol"},{"key":"1678_CR64","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/bmt.2016.71","volume":"51","author":"X He","year":"2016","unstructured":"He X, Wang Q, Cen J, Qiu H, Sun A, Chen S, et al. Predictive value of high EVI1 expression in AML patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation in first CR. Bone Marrow Transpl. 2016;51:921\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"1678_CR65","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1182\/blood-2015-07-653840","volume":"127","author":"HJMP Verhagen","year":"2016","unstructured":"Verhagen HJMP, Smit MA, Rutten A, Denkers F, Poddighe PJ, Merle PA, et al. Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid. Blood. 2016;127:458\u201363.","journal-title":"Blood"},{"key":"1678_CR66","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40487-019-0095-9","volume":"7","author":"E Paubelle","year":"2019","unstructured":"Paubelle E, Plesa A, Hayette S, Zylbersztejn F, Hermine O, Salles G, et al. Efficacy of all-trans-retinoic acid in high-risk acute myeloid leukemia with overexpression of EVI1. Oncol Ther. 2019;7:121\u201330.","journal-title":"Oncol Ther"},{"key":"1678_CR67","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.3324\/haematol.2017.178723","volume":"103","author":"T Ripperger","year":"2018","unstructured":"Ripperger T, Hofmann W, Koch JC, Shirneshan K, Haase D, Wulf G, et al. MDS1 and EVI1 complex locus (MECOM): a novel candidate gene for hereditary hematological malignancies. Haematologica. 2018;103:e55\u20138.","journal-title":"Haematologica"},{"key":"1678_CR68","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/bjh.19023","volume":"203","author":"D Ammeti","year":"2023","unstructured":"Ammeti D, Marzollo A, Gabelli M, Zanchetta ME, Tretti-Parenzan C, Bottega R, et al. A novel mutation in MECOM affects MPL regulation in vitro and results in thrombocytopenia and bone marrow failure. Br J Haematol. 2023;203:852\u20139.","journal-title":"Br J Haematol"},{"key":"1678_CR69","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1182\/bloodadvances.2018016501","volume":"2","author":"M Germeshausen","year":"2018","unstructured":"Germeshausen M, Ancliff P, estrade J, Metzler M, Ponstingl E, R\u00fctschle H, et al. MECOM-associated syndrome: a heterogeneous inherited bone marrow failure syndrome with amegakaryocytic thrombocytopenia. Blood Adv. 2018;2:586\u201396.","journal-title":"Blood Adv"},{"key":"1678_CR70","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/bjh.16534","volume":"190","author":"AS Wilhemson","year":"2020","unstructured":"Wilhemson AS, Porse BT. CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance. Br J Haematol. 2020;190:495\u2013507.","journal-title":"Br J Haematol"},{"key":"1678_CR71","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3324\/haematol.2016.151910","volume":"102","author":"F Mannelli","year":"2017","unstructured":"Mannelli F, Ponziani V, Bencini S, Bonetti M, Benelli M, Cutini I, et al. CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. Haematologica. 2017;102:529\u201340.","journal-title":"Haematologica"},{"key":"1678_CR72","doi-asserted-by":"publisher","first-page":"706935","DOI":"10.3389\/fonc.2021.706935","volume":"11","author":"LX Wu","year":"2021","unstructured":"Wu LX, Jiang H, Chang YJ, Zhou YL, Wang J, Wang ZL, et al. Risk stratification of cytogenetically normal acute myeloid leukemia with biallelic CEBPA mutations based on a multi-gene panel and nomogram model. Front Oncol. 2021;11:706935.","journal-title":"Front Oncol"},{"key":"1678_CR73","doi-asserted-by":"publisher","first-page":"628248","DOI":"10.3389\/fonc.2021.628248","volume":"11","author":"X Xu","year":"2021","unstructured":"Xu X, Cai W, Cai P, Zhang L, Yao H, Zhang T, et al. Prognostic nomogram for acute myeloid leukemia patients with biallelic CEBPA mutations. Front Oncol. 2021;11:628248.","journal-title":"Front Oncol"},{"key":"1678_CR74","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1182\/blood.2020010165","volume":"137","author":"M Duchmann","year":"2021","unstructured":"Duchmann M, Micol JB, Duployez N, Raffoux E, Thomas X, Marolleau JP, et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. Blood. 2021;137:2827\u201337.","journal-title":"Blood"},{"key":"1678_CR75","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/s41375-018-0026-z","volume":"32","author":"M Meggendorfer","year":"2018","unstructured":"Meggendorfer M, Cappelli LV, Walter W, Haferlach C, Kern W, Falini B, et al. IDH2R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and May influence targeted treatment strategies. Leukemia. 2018;32:1249\u201353.","journal-title":"Leukemia"},{"key":"1678_CR76","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/bloodadvances.2021004934","volume":"6","author":"JM Middeke","year":"2022","unstructured":"Middeke JM, Metzeler KH, R\u00f6llig C, Kr\u00e4mer M, Eckardt JN, Stasik S, et al. Differential impact of IDH1\/2 mutational subclasses on outcome in adult AML: results from a large multicenter study. Blood Adv. 2022;6:1394\u2013405.","journal-title":"Blood Adv"},{"key":"1678_CR77","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bjh.17981","volume":"196","author":"DC Linch","year":"2022","unstructured":"Linch DC, Hills RK, Burnett AK, Russell N, Gale RE. Therapy for isocitrate dehydrogenase 2 (IDH2)(R172)-mutant acute myeloid leukaemia. Br J Haematol. 2022;196:1348\u201352.","journal-title":"Br J Haematol"},{"key":"1678_CR78","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s12885-023-11034-7","volume":"23","author":"Y Qin","year":"2023","unstructured":"Qin Y, Shen K, Liu T, Ma H. Prognostic value of IDHR140 and IDHR172 mutations in patients with acute myeloid leukemia: a systematic review and meta-analysis. BMC Cancer. 2023;23:527.","journal-title":"BMC Cancer"},{"key":"1678_CR79","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722\u201331.","journal-title":"Blood"},{"key":"1678_CR80","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/blood.2020007233","volume":"137","author":"EM Stein","year":"2021","unstructured":"Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, et al. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021;137:1792\u2013803.","journal-title":"Blood"},{"key":"1678_CR81","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/bjh.17336","volume":"192","author":"S Kayser","year":"2021","unstructured":"Kayser S, Hills RK, Langova R, Kramer M, Guijarro F, Susykova Z, et al. Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an international collaborative study. Br J Haematol. 2021;192:832\u201342.","journal-title":"Br J Haematol"},{"key":"1678_CR82","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/nar\/gkt931","volume":"42","author":"I Dreveny","year":"2014","unstructured":"Dreveny I, Deeves SE, Fulton J, Yue B, Messmer M, Bhattacharya A, et al. The double PHD finger domain of MOZ\/MYST3 induces \u03b1-helical structure of the histone H3 tail to facilitate acetylation and methylation sampling and modification. Nucleic Acids Res. 2014;42:822\u201335.","journal-title":"Nucleic Acids Res"},{"key":"1678_CR83","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1182\/blood-2021-154052","volume":"138","author":"AJ Lamble","year":"2021","unstructured":"Lamble AJ, Gerbing RB, Smith JL, Ries RE, Kolb EA, Alonzo TA, et al. Crebbp alterations are associated with a poor prognosis in de Novo AML. Blood. 2021;138:3451.","journal-title":"Blood"},{"key":"1678_CR84","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00277-019-03637-7","volume":"98","author":"W Xie","year":"2019","unstructured":"Xie W, Hu S, Xu J, Chen Z, Medeiros LJ, Tang G. Acute myeloid leukemia with t(8;16)(p11.2;p13.3)\/KAT6A-CREBBP in adults. Ann Hematol. 2019;98:1149\u201357.","journal-title":"Ann Hematol"},{"key":"1678_CR85","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1182\/blood-2013-02-485524","volume":"122","author":"EA Coenen","year":"2013","unstructured":"Coenen EA, Zwaan CM, Reinhardt D, Harrison CJ, Haas OA, de Haas V, et al. Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group. Blood. 2013;122:2704\u201313.","journal-title":"Blood"},{"key":"1678_CR86","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41586-018-0387-5","volume":"560","author":"JB Baell","year":"2018","unstructured":"Baell JB, Leaver DJ, Hermans SJ, Kelly GL, Brennan MS, Downer NL, et al. Inhibitors of histone acethyltransferases KAT6A\/B induce senescence and arrest tumour growth. Nature. 2018;560:253\u20137.","journal-title":"Nature"},{"key":"1678_CR87","first-page":"1502","volume":"90","author":"U Bacher","year":"2005","unstructured":"Bacher U, Kern W, Schnittger S, Hiddemann W, Haferlach T, Schoch C. Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. Haematologica. 2005;90:1502\u201310.","journal-title":"Haematologica"},{"key":"1678_CR88","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.cancergencyto.2010.07.126","volume":"202","author":"NM Savage","year":"2010","unstructured":"Savage NM, Kota V, Manaloor EJ, Kulharya AS, Pierini V, Mecucci C, et al. Acute leukemia with PICALM-MLLT10 fusion gene: diagnostic and treatment struggle. Cancer Genet Cytogenet. 2010;202:129\u201332.","journal-title":"Cancer Genet Cytogenet"},{"key":"1678_CR89","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.leukres.2012.07.008","volume":"36","author":"C Borel","year":"2012","unstructured":"Borel C, Dastugue N, Cances-Lauwers V, Mozziconacci MJ, Prebet T, Vey N, et al. PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients. Leuk Res. 2012;36:1365\u20139.","journal-title":"Leuk Res"},{"key":"1678_CR90","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3343\/alm.2023.43.3.310","volume":"43","author":"MS Park","year":"2023","unstructured":"Park MS, Kim HY, Lee JJ, Cho D, Jung CW, Kim HJ, et al. The first case of acute myeloid leukemia with t(10;11)(p13;q21); PICALM-MLLT10 rearrangement presenting with extensive skin involvement. Ann Lab Med. 2023;43:310\u20134.","journal-title":"Ann Lab Med"},{"issue":"suppl1","key":"1678_CR91","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1182\/blood-2022-156731","volume":"140","author":"C Mark","year":"2022","unstructured":"Mark C, Kolb EA, Goemans BF, Meshinchi S, Gibson B, Bergmann AK, et al. Treatment outcomes of childhood PICALM:MLLT10\u2009+\u2009acute leukemias: an international retrospective study. Blood. 2022;140(suppl1):3403\u20134.","journal-title":"Blood"},{"key":"1678_CR92","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1365-2141.2011.08986.x","volume":"157","author":"V Grossmann","year":"2012","unstructured":"Grossmann V, Bacher U, Kohlmann A, Artusi V, Klein HU, Dugas M, et al. EZH2 mutations and their association with PICALM-MLLT10 positive acute leukaemia. Br J Haematol. 2012;157:387\u201390.","journal-title":"Br J Haematol"},{"key":"1678_CR93","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1038\/leu.2014.235","volume":"28","author":"SM Sarkaria","year":"2014","unstructured":"Sarkaria SM, Christopher MJ, Klco JM, Ley TJ. Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro. Leukemia. 2014;28:2403\u20136.","journal-title":"Leukemia"},{"key":"1678_CR94","doi-asserted-by":"publisher","first-page":"e30251","DOI":"10.1002\/pbc.30251","volume":"70","author":"KM Chisholm","year":"2023","unstructured":"Chisholm KM, Smith J, Heerema-McKenney AE, Choi JK, Ries RE, Hirsch BA, et al. Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryoblastic differentiation: a report from the children\u2019s oncology group. Pediatr Blood Cancer. 2023;70:e30251.","journal-title":"Pediatr Blood Cancer"},{"key":"1678_CR95","doi-asserted-by":"publisher","first-page":"e329","DOI":"10.1111\/bjh.16900","volume":"190","author":"Y Saito","year":"2020","unstructured":"Saito Y, Makita S, Chinen S, Kito M, Fujino T, Ida H, et al. Acute megakaryoblastic leukaemia with t(1;22)(p13.3;q13.1)\/RBM15-MKL1 in an adult patient following a non-mediastinal germ cell tumour. Br J Haematol. 2020;190:e329\u201332.","journal-title":"Br J Haematol"},{"key":"1678_CR96","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1182\/blood-2001-12-0241","volume":"100","author":"N Dastugue","year":"2002","unstructured":"Dastugue N, Lafage-Pochitaloff M, Pages MP, Radford I, Bastard C, Talmant P, et al. Cytogenetic profile of childhood and adult megakaryoblstic leukemia (M7): a study of the groupe Fran\u00e7ais de cytog\u00e9n\u00e9tique h\u00e9matologique (GFCH). Blood. 2002;100:618\u201326.","journal-title":"Blood"},{"key":"1678_CR97","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cancergencyto.2010.02.009","volume":"199","author":"G Lim","year":"2010","unstructured":"Lim G, Choi JR, Kim MJ, Kim SY, Lee HJ, Suh JT, et al. Detection of t(3;5) and NPM1\/MLF1 rearrangement in an elderly patient with acute myeloid leukemia: clinical and laboratory study with review of the literature. Cancer Genet Cytogenet. 2010;199:101\u20139.","journal-title":"Cancer Genet Cytogenet"},{"key":"1678_CR98","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jmoldx.2014.05.004","volume":"16","author":"U Aypar","year":"2014","unstructured":"Aypar U, Knudson RA, Pearce KE, Wiktor AE, Ketterking RP. Development of an NPM1\/MLF1 D-FISH probe set for the detection of t(3;5)(q25;q35) identified in patients with acute myeloid leukemia. J Mol Diagn. 2014;16:527\u201332.","journal-title":"J Mol Diagn"},{"issue":"suppl1","key":"1678_CR99","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1182\/blood.V120.21.1456.1456","volume":"120","author":"ML Alattar","year":"2012","unstructured":"Alattar ML, Kantarjian HM, Cortes JE, Kadia TM, Borthakur G, Ohanian M, et al. Incidence and outcomes of a rare translocation t(3;5) in patients (pts) with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Blood. 2012;120(suppl1):1456.","journal-title":"Blood"},{"key":"1678_CR100","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/1098-2264(2000)9999:9999<::AID-GCC1039>3.0.CO;2-9","volume":"29","author":"S Tosi","year":"2000","unstructured":"Tosi S, Harbott J, Teigler-Schlegel A, Haas OA, Pirc-Danoewinata H, Harrison CJ, et al. T(7;12)(q36;p13), a new recurrent translocation involving ETV6 in infant leukemia. Genes Chromosomes Cancer. 2000;29:325\u201332.","journal-title":"Genes Chromosomes Cancer"},{"key":"1678_CR101","doi-asserted-by":"publisher","first-page":"BSR20220489","DOI":"10.1042\/BSR20220489","volume":"43","author":"D Ragusa","year":"2023","unstructured":"Ragusa D, Dijkhuis L, Pina C, Tosi S. Mechanisms associated with t(7;12) acute myeloid leukaemia: from genetics to potential treatment targets. Biosci Rep. 2023;43:BSR20220489.","journal-title":"Biosci Rep"},{"key":"1678_CR102","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/gcc.22538","volume":"57","author":"ADL Espersen","year":"2018","unstructured":"Espersen ADL, Noren-Nystr\u00f6m U, Abrahamsson J, Ha SY, Pronk CJ, Jahnukainen K, et al. Acute myeloid leukemia (AML) with t(7;12)(q36;p13) is associated with infancy and trisomy 19: data from nordic society for pediatric hematology and oncology (NOPHO-AML) and review of the literature. Genes Chromosomes Cancer. 2018;57:359\u201365.","journal-title":"Genes Chromosomes Cancer"},{"key":"1678_CR103","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/sj.leu.2402121","volume":"15","author":"RM Slater","year":"2001","unstructured":"Slater RM, von Drunen E, Kroes WG, Weghuis DO, van den Berg E, Smit EM, et al. T(7;12)(q36;p13) and t(7;12)(q32;p13) \u2013 translocations involving ETV6 in children 18 months of age or younger with myeloid disorders. Leukemia. 2001;15:915\u201320.","journal-title":"Leukemia"},{"key":"1678_CR104","doi-asserted-by":"publisher","first-page":"539","DOI":"10.7326\/0003-4819-111-6-539","volume":"111","author":"A Domingo","year":"1989","unstructured":"Domingo A, Romagosa V, Callis M, Vivancos P, Guionnet N, Soler J. Mediastinal germ cell tumor and acute megakaryo-blastic leukemia. Ann Intern Med. 1989;111:539.","journal-title":"Ann Intern Med"},{"key":"1678_CR105","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3109\/08880019209018329","volume":"9","author":"A Zipursky","year":"1992","unstructured":"Zipursky A, Poon A, Doyle J. Leukemia in down syndrome: a review. Pediatr Hematol Oncol. 1992;9:139\u201349.","journal-title":"Pediatr Hematol Oncol"},{"key":"1678_CR106","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/ng.3772","volume":"49","author":"JDE De Rooij","year":"2017","unstructured":"De Rooij JDE, Branstetter C, Ma J, Li Y, Walsh MP, Cheng J, et al. Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. Nat Genet. 2017;49:451\u20136.","journal-title":"Nat Genet"},{"key":"1678_CR107","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cell.2012.06.032","volume":"150","author":"Q Wen","year":"2012","unstructured":"Wen Q, Goldenson B, Silver SJ, Schenone M, Dancik V, Huang Z, et al. Identification of regulators of polyploidization presents therapeutic targets for treatment Og AMKL. Cell. 2012;150:575\u201389.","journal-title":"Cell"},{"key":"1678_CR108","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-19-1005","volume":"25","author":"N Gangat","year":"2019","unstructured":"Gangat N, Marinaccio C, Swords R, Watts JM, Gurbuxani S, Rademaker A, et al. Aurora kinase A Inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis. Clin Cancer Res. 2019;25:4898\u2013906.","journal-title":"Clin Cancer Res"},{"key":"1678_CR109","first-page":"450","volume":"4","author":"N Cervera","year":"2023","unstructured":"Cervera N, Guille A, Adelaide J, Hospital MA, Garciaz S, Mozziconacci MJ, et al. Erythroleukemia: classification. Eur J Haem. 2023;4:450\u20133.","journal-title":"Eur J Haem"},{"key":"1678_CR110","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41588-019-0375-1","volume":"51","author":"I Iacobucci","year":"2019","unstructured":"Iacobucci I, Wen J, Meggendorfer M, Choi JK, Shi L, Pounds SB, et al. Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nat Genet. 2019;51:694\u2013704.","journal-title":"Nat Genet"},{"key":"1678_CR111","doi-asserted-by":"publisher","first-page":"6256","DOI":"10.3390\/ijms25116256","volume":"25","author":"P Fernandes","year":"2024","unstructured":"Fernandes P, Waldron N, Chatzilygeroudi T, Naji NS, Karantanos T. Acute erythroid leukemia: from molecular biology to clinical outcomes. Int J Mol SCi. 2024;25:6256.","journal-title":"Int J Mol SCi"},{"key":"1678_CR112","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1182\/blood.2020009103","volume":"137","author":"I Iacobucci","year":"2021","unstructured":"Iacobucci I, Qu C, Varotto E, Janke LJ, Yang X, Seth A, et al. Modeling and targeting of erythroleukemia by hematopoietic genome editing. Blood. 2021;137:1628\u201340.","journal-title":"Blood"},{"key":"1678_CR113","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1182\/blood.2021011094","volume":"141","author":"H Kuusanmaki","year":"2023","unstructured":"Kuusanmaki H, Dufva O, Vaha-Koskela M, Leppa AM, Huuhtanen J, Vanttinen I, et al. Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia. Blood. 2023;141:1610\u201325.","journal-title":"Blood"},{"key":"1678_CR114","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1002\/ccr3.1219","volume":"5","author":"Y Toda","year":"2017","unstructured":"Toda Y, Nagai Y, Shimomura D, Kishimori C, Tsuda K, Fukutsuka K, et al. Acute basophilic leukemia associated with the t(16;21)(p11;q22)\/FUS-ERG fusion gene. Clin Case Rep. 2017;5:1938\u201344.","journal-title":"Clin Case Rep"},{"key":"1678_CR115","doi-asserted-by":"publisher","first-page":"7095","DOI":"10.1111\/jcmm.16591","volume":"25","author":"T Shimizu","year":"2021","unstructured":"Shimizu T, Kondo T, Nannya Y, Watanabe M, Kitawaki T, Shindo T, et al. Next-generation sequencing in two cases of de Novo acute basophilic leukaemia. J Cell Mol Med. 2021;25:7095\u20139.","journal-title":"J Cell Mol Med"},{"key":"1678_CR116","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11154-016-9362-3","volume":"17","author":"LW Greene","year":"2016","unstructured":"Greene LW, Asadipooya K, Corradi PF, Akin C. Endocrine manifestations of systemic mastocytosis in bone. Rev Endocr Metab Disord. 2016;17:419\u201331.","journal-title":"Rev Endocr Metab Disord"},{"key":"1678_CR117","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","volume":"121","author":"S Georgin-Lavialle","year":"2013","unstructured":"Georgin-Lavialle S, Lhermitte L, Dubreuil P, Chandesris MO, Hermine O, Damaj G. Mast cell leukemia. Blood. 2013;121:1285\u201395.","journal-title":"Blood"},{"key":"1678_CR118","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.bcmd.2005.08.006","volume":"35","author":"MA Lichtman","year":"2005","unstructured":"Lichtman MA, Segel GB. Uncommon phenotypes of acute myelogenous leukemia: basophilic, mast cell, eosinophilic, and myeloid dendritic cell subtypes: a review. Blood Cells Mol Dis. 2005;35:370\u201383.","journal-title":"Blood Cells Mol Dis"},{"key":"1678_CR119","doi-asserted-by":"publisher","first-page":"6037","DOI":"10.4049\/jimmunol.165.11.6037","volume":"165","author":"A Dzionek","year":"2000","unstructured":"Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol. 2000;165:6037\u201346.","journal-title":"J Immunol"},{"key":"1678_CR120","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1600-0560.2011.01777.x","volume":"38","author":"JL Dargent","year":"2011","unstructured":"Dargent JL, Delannoy A, Pieron P, Husson B, Debecker C, Petrella T. Cutaneous accumulation of plasmacytoid dendritic cells associated with acute myeloid leukemia: a rare condition distinct from blastic plasmacytoid dendritic cell neoplasm. J Cutan Pathol. 2011;38:893\u20138.","journal-title":"J Cutan Pathol"},{"key":"1678_CR121","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cyto.a.23953","volume":"97","author":"Y Huang","year":"2020","unstructured":"Huang Y, Wang Y, Chang Y, Yuan X, Hao L, Shi H, et al. Myeloid neoplams with elevated plasmacytoid dendritic cell differentiation reflect the maturation process of dendritic cells. Cytometry A. 2020;97:61\u20139.","journal-title":"Cytometry A"},{"key":"1678_CR122","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00277-013-1744-y","volume":"92","author":"M Rickmann","year":"2013","unstructured":"Rickmann M, Macke L, Sundarasetty BS, Stamer K, Figueiredo C, Blasczyk R, et al. Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia. Ann Hematol. 2013;92:1079\u201390.","journal-title":"Ann Hematol"},{"key":"1678_CR123","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1182\/blood.2020007897","volume":"137","author":"W Xiao","year":"2021","unstructured":"Xiao W, Chan A, Waarts MR, Mishra T, Liu Y, Cai SF, et al. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood. 2021;137:1377\u201391.","journal-title":"Blood"},{"key":"1678_CR124","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa025217","volume":"348","author":"J Cools","year":"2003","unstructured":"Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of Imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201\u201314.","journal-title":"N Engl J Med"},{"key":"1678_CR125","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1080\/10428194.2016.1197396","volume":"58","author":"M Maccaferri","year":"2017","unstructured":"Maccaferri M, Pierini V, Di Giacomo D, Zucchini P, Forghieri F, Bonacorsi G, et al. The importance of cytogenetic and molecular analyses in eosinophilia-associated myeloproliferative neoplasms: an unusual case with normal karyotype and TNIP1-PDGFRB rearrangement and overview of PDGFRB partner genes. Leuk Lymphoma. 2017;58:489\u201393.","journal-title":"Leuk Lymphoma"},{"key":"1678_CR126","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3324\/haematol.2011.047530","volume":"97","author":"CP Montano-Almendras","year":"2012","unstructured":"Montano-Almendras CP, Essaghir A, Scoemans H, Varis I, No\u00ebl LA, Velghe AI, et al. ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-kB. Haematologica. 2012;97:1064\u201372.","journal-title":"Haematologica"},{"key":"1678_CR127","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.humpath.2009.11.003","volume":"41","author":"CC Jackson","year":"2010","unstructured":"Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol. 2010;41:461\u201376.","journal-title":"Hum Pathol"},{"key":"1678_CR128","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/his.15021","volume":"83","author":"L Saft","year":"2023","unstructured":"Saft L, Kvasnicka HM, Boudova L, Gianelli U, Lazzi S, Rozman M. Myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: a workshop report with focus on novel entities and a literature review including paediatric cases. Histopathology. 2023;83:829\u201349.","journal-title":"Histopathology"},{"key":"1678_CR129","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/sj.leu.2404662","volume":"21","author":"G Metzgeroth","year":"2007","unstructured":"Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia. 2007;21:1183\u20138.","journal-title":"Leukemia"},{"key":"1678_CR130","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3324\/haematol.2016.144345","volume":"101","author":"M Zaliova","year":"2016","unstructured":"Zaliova M, Moorman AV, Cazzaniga G, Stanulla M, Harvey RC, Roberts KG, et al. Characterization of leukemias with ETV6-ABL1 fusion. Haematologica. 2016;101:1082\u201393.","journal-title":"Haematologica"},{"key":"1678_CR131","first-page":"614","volume":"106","author":"J Yao","year":"2021","unstructured":"Yao J, Xu L, Aypar U, Meyerson HJ, Londono D, Gao Q, et al. Myeloid\/lymphoid neoplasms with eosinophilia\/basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase Inhibition. Haematologica. 2021;106:614\u20138.","journal-title":"Haematologica"},{"key":"1678_CR132","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/ajh.25825","volume":"95","author":"J Schwaab","year":"2020","unstructured":"Schwaab J, Naumann N, Luebke J, Jawhar M, Somervaille TCP, Williams MS, et al. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. Am J Hematol. 2020;95:824\u201333.","journal-title":"Am J Hematol"},{"key":"1678_CR133","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 matation. N Engl J Med. 2017;377:454\u201364.","journal-title":"N Engl J Med"},{"key":"1678_CR134","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Zak P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1571\u201383.","journal-title":"Lancet"},{"key":"1678_CR135","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1200\/JCO.22.02721","volume":"41","author":"KW Pratz","year":"2023","unstructured":"Pratz KW, Cherry M, Altman JK, Cooper BW, Podoltsev NA, Cruz JC, et al. Gilteritinib in combination with induction and consolidation chemotherapy and as maintenance therapy: a phase IB study in patients with newly diagnosed AML. J Clin Oncol. 2023;41:4236\u201346.","journal-title":"J Clin Oncol"},{"key":"1678_CR136","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","volume":"21","author":"L Xuan","year":"2020","unstructured":"Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic Haematopoietic stem-cell transplantation: an open-label, multicentre, randomized phase 3trial. Lancet Oncol. 2020;21:1201\u201312.","journal-title":"Lancet Oncol"},{"key":"1678_CR137","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","volume":"38","author":"A Burchert","year":"2020","unstructured":"Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, R\u00f6llig C, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation. J Clin Oncol. 2020;38:2993\u20133002.","journal-title":"J Clin Oncol"},{"key":"1678_CR138","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.3390\/cancers15143589","volume":"15","author":"E Oyogoa","year":"2023","unstructured":"Oyogoa E, Traer E, Tyner J, Lachowiez C. Building on foundations: venetoclax-based combinations in the treatment of acute myeloid leukemia. Cancers. 2023;15:3589.","journal-title":"Cancers"},{"key":"1678_CR139","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, et al. Ivosidenib and Azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386:1519\u201331.","journal-title":"N Engl J Med"},{"key":"1678_CR140","doi-asserted-by":"publisher","first-page":"7012","DOI":"10.1200\/JCO.2023.41.16_suppl.7012","volume":"41","author":"S De Botton","year":"2023","unstructured":"De Botton S, Montesinos P, Polo S, Zarzycka E, Wang J, Riva M, et al. Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib\u2009+\u2009azacitidine compared to placebo\u2009+\u2009azacitidine. J Clin Oncol. 2023;41:7012.","journal-title":"J Clin Oncol"},{"key":"1678_CR141","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40487-024-00262-x","volume":"12","author":"X Thomas","year":"2024","unstructured":"Thomas X. Small molecule Menin inhibitors: novel therapeutic agents targeting acute myeloid leukemia with KMT2A rearrangement or NPM1 mutation. Oncol Ther. 2024;12:57\u201372.","journal-title":"Oncol Ther"},{"key":"1678_CR142","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and Daunorubicin) liposome for injection versus conventional cytarabine plus Daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36:2684\u201392.","journal-title":"J Clin Oncol"},{"key":"1678_CR143","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/14728214.2022.2094365","volume":"27","author":"X Thomas","year":"2022","unstructured":"Thomas X, Elhamri M, Deloire A, Heiblig M. Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials. Expert Opin Emerg Drugs. 2022;27:169\u201385.","journal-title":"Expert Opin Emerg Drugs"},{"key":"1678_CR144","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","volume":"4","author":"CA Lachowiez","year":"2023","unstructured":"Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, et al. A phase Ib\/II study of Ivosidenib with venetoclax\u2009\u00b1\u2009azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov. 2023;4:276\u201393.","journal-title":"Blood Cancer Discov"},{"key":"1678_CR145","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41408-022-00670-0","volume":"12","author":"M Yilmaz","year":"2022","unstructured":"Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, et al. Hypomethylating agent and venetoclax with FLT3 inhibitor triplet therapy in older\/unfit patients with FLT3 mutated AML. Blood Cancer J. 2022;12:77.","journal-title":"Blood Cancer J"},{"key":"1678_CR146","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ, Daver N, DiNardo CD, Kadia T, Nasr LF, Macaron W, et al. Azacitidine, Venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol. 2024;42:1499\u2013508.","journal-title":"J Clin Oncol"},{"key":"1678_CR147","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","volume":"11","author":"G Garcia-Manero","year":"2024","unstructured":"Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, et al. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomized, crossover, pharmaceutics, phase 3 study. Lancet Haematol. 2024;11:e15\u201326.","journal-title":"Lancet Haematol"},{"key":"1678_CR148","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","volume":"383","author":"AH Wei","year":"2020","unstructured":"Wei AH, D\u00f6hner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, et al. Oral Azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020;383:2526\u201337.","journal-title":"N Engl J Med"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01678-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01678-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01678-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T07:03:15Z","timestamp":1751612595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01678-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":148,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["1678"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01678-y","relation":{},"ISSN":["1534-6269"],"issn-type":[{"type":"electronic","value":"1534-6269"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"11 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by the author.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The author declares no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}